Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Elusys Therapeutics, Inc. (Elusys) gab heute bekannt, dass die Europäische Kommission Obiltoxaximab, das monoklonale Antikörper (mAb)...
Elusys Therapeutics, Inc. (« Elusys ») a annoncé aujourd'hui que la Commission européenne a autorisé la commercialisation de l'obiltoxaximab,...
Elusys Therapeutics, Inc. (Elusys) anunció hoy que la Comisión Europea ha aprobado obiltoxaximab, la antitoxina de ántrax de anticuerpo monoclonal...
Elusys Therapeutics, Inc. (Elusys) today announced that the European Commission has approved obiltoxaximab, the company's monoclonal antibody (mAb)...
Elusys Therapeutics, Inc. (Elusys) a annoncé aujourd'hui que le Committee for Medicinal Products for Human Use (CHMP) de l'Agence européenne des...
Elusys Therapeutics, Inc. (Elusys) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, CHMP) ...
Elusys Therapeutics, Inc. (Elusys) anunció hoy que el Committee for Medicinal Products for Human Use (CHMP) de la Agencia Europea de Medicamentos ha...
Elusys Therapeutics, Inc. (Elusys) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Elusys Therapeutics, Inc. (Elusys) announced today that it has been awarded a $25.2 million follow-on Delivery Order (DO) by the U.S. Government for...
Elusys Therapeutics, Inc. (Elusys) announced today that the company has delivered the first doses of ANTHIM® (obiltoxaximab) Injection, its treatment ...
Elusys Therapeutics, Inc. (Elusys) today announced it has received $16.35 million for completing the second delivery of ANTHIM® (obiltoxaximab)...
Elusys Therapeutics, Inc. (Elusys) today announced that the company published data and analyses used to determine the intravenous adult human dose...
Elusys Therapeutics, Inc. (Elusys) today announced that the company published data on over 450 healthy adult subjects from five clinical trials used...
Elusys Therapeutics, Inc. (Elusys) today announced that two important manuscripts describing animal efficacy of ANTHIM (obiltoxaximab) Injection in...
Elusys Therapeutics, Inc. (Elusys) today announced that the U.S. Food and Drug Administration (FDA) has approved ANTHIM (obiltoxaximab) Injection,...
Elusys Therapeutics, Inc. (Elusys) today announced it has been awarded its first delivery order under a procurement contract for Anthim...
Elusys Therapeutics, Inc. (Elusys) today announced it has been awarded $16 million of additional funding from the U.S. Government to further advance...
Elusys Therapeutics, Inc. (Elusys) today announced the U.S. Food and Drug Administration (FDA) has accepted for filing and review its Biologics...
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data...
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has...
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced that it...
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, announced that the United...
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented key findings...
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today released data from...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.